BPTF and melanoma: Additionally, other factors such as bromodomain PHD finger transcription factor (BPTF) [63], glioma-associated oncogene homolog 1 and 2 (GLI1, GLI2) [64], c-FOS, JunB proto-oncogene (JUNB), ETS proto-oncogene 2 (ETS2), and ETS variant transcription factor 1 (ETV1) [65] have been associated with melanoma progression and treatment resistance.